Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $21.9 in the prior trading day, Elanco Animal Health Inc (NYSE: ELAN) closed at $21.69, down -0.96%. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 5.99 million shares were traded. ELAN stock price reached its highest trading level at $22.1896 during the session, while it also had its lowest trading level at $21.53.
Ratios:
Our goal is to gain a better understanding of ELAN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.34 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.29. For the most recent quarter (mrq), Quick Ratio is recorded 1.23 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.59.
Upgrades & Downgrades
In the most recent recommendation for this company, KeyBanc Capital Markets on November 21, 2025, initiated with a Overweight rating and assigned the stock a target price of $27.
On November 19, 2025, Argus Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $25.
JP Morgan Upgraded its Neutral to Overweight on October 07, 2025, while the target price for the stock was maintained at $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Todd S and Jennifer G Young Li bought 49,333 shares for $16.82 per share.
Kurzius Lawrence Erik bought 10,000 shares of ELAN for $109,000 on Mar 07 ’25. The Director now owns 101,459 shares after completing the transaction at $10.90 per share. On Mar 11 ’25, another insider, Kurzius Lawrence Erik, who serves as the Director of the company, bought 10,000 shares for $10.20 each. As a result, the insider paid 102,000 and bolstered with 111,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELAN now has a Market Capitalization of 10776969216 and an Enterprise Value of 14400310272. As of this moment, Elanco’s Price-to-Earnings (P/E) ratio for their current fiscal year is 297.53, and their Forward P/E ratio for the next fiscal year is 21.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 35.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.35 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 3.137 whereas that against EBITDA is 16.327.
Stock Price History:
The Beta on a monthly basis for ELAN is 1.88, which has changed by 0.76328504 over the last 52 weeks, in comparison to a change of 0.13844287 over the same period for the S&P500. Over the past 52 weeks, ELAN has reached a high of $23.70, while it has fallen to a 52-week low of $8.02. The 50-Day Moving Average of the stock is 0.41%, while the 200-Day Moving Average is calculated to be 39.22%.
Shares Statistics:
The stock has traded on average 5.33M shares per day over the past 3-months and 4667320 shares per day over the last 10 days, according to various share statistics. A total of 496.83M shares are outstanding, with a floating share count of 492.27M. Insiders hold about 0.92% of the company’s shares, while institutions hold 115.67% stake in the company. Shares short for ELAN as of 1763078400 were 22453561 with a Short Ratio of 4.21, compared to 1760486400 on 24797955. Therefore, it implies a Short% of Shares Outstanding of 22453561 and a Short% of Float of 6.25.
Earnings Estimates
. The current rating of Elanco Animal Health Inc (ELAN) reflects the combined expertise of 11.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.35, with high estimates of $0.38 and low estimates of $0.3.
Analysts are recommending an EPS of between $1.05 and $0.91 for the fiscal current year, implying an average EPS of $0.94. EPS for the following year is $1.04, with 14.0 analysts recommending between $1.11 and $0.98.
Revenue Estimates
10 analysts predict $1.09B in revenue for. The current quarter. It ranges from a high estimate of $1.11B to a low estimate of $1.08B. As of. The current estimate, Elanco Animal Health Inc’s year-ago sales were $1.02BFor the next quarter, 10 analysts are estimating revenue of $1.27B. There is a high estimate of $1.28B for the next quarter, whereas the lowest estimate is $1.25B.
A total of 12 analysts have provided revenue estimates for ELAN’s current fiscal year. The highest revenue estimate was $4.73B, while the lowest revenue estimate was $4.65B, resulting in an average revenue estimate of $4.67B. In the same quarter a year ago, actual revenue was $4.44BBased on 12 analysts’ estimates, the company’s revenue will be $4.92B in the next fiscal year. The high estimate is $5.01B and the low estimate is $4.82B.
